Jubilant Pharma Limited, Singapore (JPL), a wholly owned subsidiary, in November 2020 invested US$ 25 million in Sofie Biosciences USA (Sofie) and currently holds 25.8% stake.

Sofie is engaged in developing and delivering molecular diagnostics and therapeutics (theranostics). It has radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property.

Sofie has now entered into a definitive merger agreement with certain private equity funds managed by [Trilantic Capital Partners, North America ('Trilantic North America')], a US private equity firm. The merger transaction is expected to close by 30th June 2024, subject to customary conditions and regulatory approvals.

Consequently, JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million, including certain preferred returns. Of this, US$ 113.63 million (subject to certain customary adjustments at closing) is expected to be received upon completion of the merger while receipt of balance sum of US$ 25.8 million is contingent upon achievement of certain future milestones. JPL plans to use these proceeds to reduce leverage and for capex and other corporate purposes.